Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Stock Has Average Target Price of $37.25

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) has been assigned an average rating of “Moderate Buy” from the seven ratings firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, four have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $37.25.

A number of equities analysts recently issued reports on the company. Weiss Ratings raised Zai Lab from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 29th. Citigroup boosted their price target on Zai Lab from $44.00 to $45.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Zacks Research raised Zai Lab from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 7th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zai Lab in a research report on Tuesday, October 6th. Finally, Wall Street Zen upgraded Zai Lab from a “sell” rating to a “hold” rating in a research note on Saturday, September 26th.

Zai Lab Stock Performance

Shares of Zai Lab stock opened at $24.03 on Friday. Zai Lab has a 1 year low of $15.96 and a 1 year high of $28.11. The company has a market capitalization of $2.73 billion, a P/E ratio of -14.05 and a beta of 0.73. The company’s fifty day moving average is $25.23 and its two-hundred day moving average is $21.78.

Zai Lab (NASDAQ:ZLAB) last posted its quarterly earnings data on Tuesday, June 30th. The company reported ($0.50) EPS for the quarter. Zai Lab had a negative net margin of 41.86% and a negative return on equity of 27.43%. The business had revenue of $106.31 million during the quarter. As a group, equities analysts expect that Zai Lab will post -2.37 earnings per share for the current year.

Insider Activity

In other news, Director William Lis sold 8,506 shares of the company’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $25.00, for a total transaction of $212,650.00. Following the completion of the sale, the director owned 41,931 shares in the company, valued at $1,048,275. This represents a 16.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders sold a total of 9,385 shares of company stock valued at $235,145 over the last quarter. Insiders own 4.88% of the company’s stock.

Hedge Funds Weigh In On Zai Lab

A number of hedge funds and other institutional investors have recently bought and sold shares of ZLAB. Nykredit A S acquired a new position in Zai Lab in the 2nd quarter valued at $79,000. WealthPlan Investment Management LLC acquired a new stake in shares of Zai Lab in the 3rd quarter worth $969,000. Headlands Technologies LLC lifted its stake in shares of Zai Lab by 142.0% in the 2nd quarter. Headlands Technologies LLC now owns 68,010 shares of the company’s stock worth $1,292,000 after acquiring an additional 39,901 shares during the period. Finally, Seven Fleet Capital Management LP lifted its stake in shares of Zai Lab by 74.7% in the 2nd quarter. Seven Fleet Capital Management LP now owns 136,016 shares of the company’s stock worth $2,584,000 after acquiring an additional 58,158 shares during the period. 41.65% of the stock is currently owned by hedge funds and other institutional investors.

Zai Lab Company Profile

Zai Lab Ltd. (NASDAQ:ZLAB) is a biopharmaceutical company focused on discovering, developing and commercializing medicines for cancer and other serious diseases. Its research and development activities have included oncology, autoimmune and inflammatory disorders, neuroscience, infectious diseases and other areas of significant unmet medical need.

Founded in 2014, Zai Lab has built its business through a combination of internally developed programs and licensing or collaboration agreements with international pharmaceutical and biotechnology companies.